Substance / Medication

Telavancin

Overview

Active Ingredient
telavancin
RxNorm CUI
473837

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

3 trials linked to this intervention

3
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.
Polyzos Konstantinos A, Mavros Michael N, Vardakas Konstantinos Z et al. · PLoS One · 2012
PMID: 22916113Meta-AnalysisFull text (PMC)
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
Stryjewski Martin E, Barriere Steven L, O'Riordan William et al. · J Antimicrob Chemother · 2012
PMID: 22416054Meta-Analysis
Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.
Wong Shekman L, Barriere Steven L, Kitt Michael M et al. · J Antimicrob Chemother · 2008
PMID: 18586659RCT
A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.
Ullah Sami, Matzneller Peter, Zeitlinger Markus et al. · Naunyn Schmiedebergs Arch Pharmacol · 2019
PMID: 31062064Trial
Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
Kidd James M, Sakon Colleen M, Oleksiuk Louise-Marie et al. · Antimicrob Agents Chemother · 2019
PMID: 31685468TrialFull text (PMC)
Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer.
Chaftari Anne-Marie, Hachem Ray, Jordan Mary et al. · Antimicrob Agents Chemother · 2016
PMID: 26482312TrialFull text (PMC)
Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment.
Worboys Philip D, Wong Shekman L, Barriere Steven L · Eur J Clin Pharmacol · 2015
PMID: 25939708TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Telavancin (substance)
SNOMED CT
443553004
UMLS CUI
C1453642
RxNorm CUI
473837

Clinical Data

This intervention maps to 10 entities in the Ltrl knowledge graph.

5
Conditions
2
Biomarkers
2
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.